Enable AI-poweredDetect new paradigm

Redefining on-site detection with chips and algorithms

About Us

Hangzhou BioChip.AI Co., Ltd. was established in March 2025. Leveraging globally leading ultra-high-density novel biochip technology (hereinafter referred to as the “novel biochip”), the company can rapidly, conveniently, simply, cost-effectively, and portably detect a wide variety of targets—including nucleic acids, proteins, and metabolites—to generate massive volumes of data. This enables the detection and characterization of complex, dynamic systems such as immune systems and microecosystems, making possible a new AI-powered detection paradigm.

At the same time, the company’s companion portable instruments allow on-site sample testing anytime and anywhere, greatly improving turnaround time while eliminating the risks and costs associated with sample transportation. Its core technologies and solutions hold diverse future application scenarios across multiple industries. They can drive innovation and transformation in areas such as respiratory pathogen detection and the relationship between gut and oral microbiota and wellness, while also delivering continuous value in smart agriculture (e.g., dairy and livestock industries), soil microorganism and soil ecology monitoring and regulation, synthetic biology (e.g., liquid fermentation microbial community refining and optimization), and AI multimodal big-data algorithms and platform development. As such, the company enjoys broad market prospects and significant potential social value.

The company’s core technical team brings together multidisciplinary talent spanning molecular diagnostics, bioinformatics, artificial intelligence, semiconductor nanofabrication, and microfluidic precision instrumentation. Team members are graduates of Tsinghua University, Peking University, and the Harbin Institute of Technology, and are joined by a professor from Westlake University. Through cross-disciplinary collaborative innovation, the team integrates cutting-edge technologies and innovative strengths from each field, establishing core technologies and fabrication processes for ultra-high-density novel biochips that are unprecedented worldwide.

Bowei Intelligent Brand Story

Professional Team

Interdisciplinary collaborative innovation, integrating cutting-edge technologies

Xu Junpu

ChairmanMBA

  • B.S., Biology, Tsinghua University
  • MBA, CTU, USA
  • Founder of Beijing ACCB Biotech
  • 20 years of IVD industry experience
  • Outstanding Overseas-Returned Entrepreneur of Zhongguancun
  • Top 10 Leading Talent in Jiaxing

Prof. Li Xijun

Chief Scientist

  • Director, Chip Digital Manufacturing Technology Research Center, Westlake University
  • Proposer of the world’s first programmable photolithography mask
  • Zhejiang Province Distinguished Expert
  • Early pioneer of LNoI
  • 40+ international patents; focused on micro/nano fabrication and maskless lithography

Mr. Chen

Technical Director

  • Ph.D., School of Life Sciences, Tsinghua University
  • Joint training at UCSF
  • Beijing Nova Program recipient
  • Beijing Science and Technology Award recipient

Mr. Hou

Bioinformatics Director

  • M.S. in Bioinformatics, Harbin Institute of Technology
  • Former mNGS project lead at EUROIMMUN China Medical Diagnostics
  • Formerly responsible for bioinformatics analysis at Gene-X Health and Annoroad

Our Journey

Innovate continuously, move forward steadily.

2026.07

Oral microecology detection automation device approved and generating sales revenue

2026.03

Launched automated POCT device for oral microecology detection

2025.12

Completed first mass-production tape-out of oral microbiota detection biochips

2025.09

Closed Pre-A round financing

2025.09

Applied for Chinese invention patents (DMD + vapor-phase synthesis)

2025.08

Filed US core patent PCT application

Let's work together to shape the future of precision testing.

Contact Us / Schedule a Consultation